Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer
Fifth Cambridge Conference
June 2005
Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement
SE Come, AU Buzdar, JN Ingle, CL Arteaga, M Brown, M Dowsett, SG Hilsenbeck, R Kumar, SRD Johnston, AV Lee, S Paik, KI Pritchard, EP Winer, C Hart
Novel Mechanisms of Resistance to Endocrine Therapy - Genomic and Nongenomic Considerations
AE Gururaj, SK Rayala, RK Vadlamudi, and R Kumar
ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors
I Shin, T Miller, and CL Arteaga
Progesterone Receptor Loss Correlates with HER2 Overexpression in Estrogen Receptor-Positive Breast Cancer
H-J Kim, X Cui, SG Hilsenbeck, and AV Lee
Methods for Gene Expression Profiling in Clinical Trials of Adjuvant Breast Cancer Therapy
S Paik
Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer
M Dowsett, IE Smith, SR Ebbs, JM Dixon, A Skene, C Griffith, I Boeddinghaus, J Salter, S Detre, M Hills, S Ashley, S Francis, G Walsh, and R A'Hern
Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer
JN Ingle
Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data
AU Buzdar and J Cuzick
Is There a Role for Adjuvant Tamoxifen in Progesterone Receptor-Positive Breast Cancer? An In Silico Clinical Trial
SG Hilsenbeck and CK Osborne
Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues
TJ Whelan and KI Pritchard
Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against EGFR / HER2 and mTOR in Breast Cancer
SRD Johnston
